ClinicalTrials.gg
CompletedNCT01119950Updated Mar 23, 2015Results posted

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of NVA237 12.5 µg once daily and NVA237 25.0 µg once daily in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 29 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-03-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
28th of 73
388 · median 152
Started
2010
with 4 others
Phase 2
19 of 73
none open now
Registered
11th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 28th largest by enrollment, is one of 5 that started in 2010, is one of 19 in phase 2, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study was designed to investigate the efficacy and safety of NVA237, a long-acting muscarinic antagonist, in patients with moderate to severe COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients age 40 years or more
  • Diagnosis of Chronic Obstructive Lung Disease () (moderate to severe as classified by the Global Initiative for COPD (GOLD) Guidelines, 2008
  • Smoking history of at least 10 pack-years
  • Post-bronchodilator (FEV1) \<80% and ≥30% of the predicted normal value
  • Post-bronchodilator FEV1/Forced Vital Capacity (FVC) \<0.7
  • Symptomatic patients, according to daily electronic diary data between visit 2 (Day -8) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to visit 3

Exclusion criteria

Exclusion Criteria:

  • Patients who have had a exacerbation requiring systemic and/or antibiotics and/or hospitalization in the 6 weeks prior to the first visit
  • Patients who have had a respiratory tract infection within 4 weeks prior to the first visit
  • Patients with concomitant pulmonary disease
  • Patients with diabetes Type I or uncontrolled diabetes Type II
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular co-morbid conditions
  • Patients with a history of asthma or a blood eosinophil count >600/mm3 or onset of symptoms prior to 40 years
  • Patients with eczema, known high IgE levels or a known positive skin prick test
  • Patients participating in the active phase of a pulmonary rehabilitation programme
  • Patients for the treatment with anticholinergics, long and short-acting beta-2 agonists or sympathomimetic amines
  • Patients with a history of alpha-1 anti-trypsin deficiency
  • Patients on long term oxygen therapy (>15hr per day)
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    NVA237 12.5 µg q.d.

    NVA237 12.5 µg once daily

    Drug: NVA237 12.5 µg once daily

  • Experimental
    NVA237 25.0 µg q.d.

    NVA237 25.0 µg once daily

    Drug: NVA237 25.0 µg once daily

  • Experimental
    NVA237 12.5 µg b.i.d.

    NVA237 12.5 µg twice daily

    Drug: NVA237 12.5 µg twice daily

  • Experimental
    NVA237 50.0 µg q.d.

    NVA237 50.0 µg once daily

    Drug: NVA237 50.0 µg once daily

  • Experimental
    NVA237 25.0 µg b.i.d.

    NVA237 25.0 µg twice daily

    Drug: NVA237 25.0 µg twice daily

  • Experimental
    NVA237 100.0 µg q.d.

    NVA237 100.0 µg once daily

    Drug: NVA237 100.0 µg once daily

  • Experimental
    NVA237 50.0 µg b.i.d.

    NVA237 50.0 µg twice daily

    Drug: NVA237 50.0 µg twice daily

  • Placebo comparator
    Placebo

    Placebo to NVA237 once daily

    Drug: Placebo to NVA237 once daily

Interventions

  • NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

  • NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

  • NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.

  • NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

  • NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.

  • NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

  • NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.

  • DrugPlacebo to NVA237 once daily

    Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.

06

What researchers measure

Primary outcomes

  1. Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 28

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. The maximal response of incremental once daily and twice daily doses of NVA237 that each dose achieves in relation to the maximal effect of NVA237 on Trough FEV1 was measured at Day 28. FEV1 was measured in response to all doses administered (see Outcome Measure #19). All trough FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All trough FEV1 data are reported as a percentage of the theoretical maximal response. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

    Time frame: Day 28

Secondary outcomes

  1. Trough Forced Expiratory Volume in One Second for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. FEV1 was measured between dosing regimens (over the range 20 micrograms to 55 micrograms total daily dose) after 28 days of treatment. Mean trough FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 19), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens. The theoretical responses to each dosing schedule separately and the difference between the once-daily and twice-daily regimens are represented below.

    Time frame: day 28

  2. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours at day 28 of treatment was calculated from measurements taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #20). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28

  3. Forced Expiratory Volume in One Second AUC 0-24 Hours for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237, After 28 Days of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. The Area Under the Curve (AUC) 0-24 hours FEV1 between dosing regimens over the range 20 micrograms to 55 micrograms total daily dose at -25 min,-15 min (predose); 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. AUC 0-24 hours FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 20), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens.

    Time frame: -25 min,-15 min (predose); 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28

  4. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours) on Day 28

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours were calculated from measurements taken at: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #21). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28

  5. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response within different doses/regimens of NVA237 was measured using FEV1 at 12 hours on day 28 of treatment. FEV1 was measured in response to all doses administered (see Outcome Measure #22). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: 12 hours on day 28

  6. Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Peak FEV1 was measured at day 28 of treatment. Peak FEV1 was measured in response to all doses administered (see Outcome Measure #23). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: day 28

  7. Percentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment

    Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Forced Vital Capacity (FVC) was measured at day 28 of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC at day 28 of treatment was measured via spirometry (see Outcome Measure #24). All FVC responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FVC data are reported as a percentage of the theoretical maximal response.

    Time frame: day 28

  8. Percentage of the Maximal Response of NVA237 Doses on Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on Trough FEV1 was measured on Days 1, 7 and 14. Through FEV1 was measured in response to all doses administered (see Outcome Measure #25). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

    Time frame: Days 1, 7 and 14

  9. Percentage of the Maximal Effect of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours, was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14. FEV1 AUC 0-24 hours was measured on days 1 and 14 of treatment in response to all doses administered (see Outcome Measure #26). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14

  10. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 hours was calculated from measurements taken at 5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14, in response to all doses administered (see Outcome Measure #27). All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: 5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14

  11. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #28). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14

  12. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14 in response to all doses administered (see Outcome Measure #29). All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14

  13. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #30). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14

  14. Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14. FEV1 was measured in response to all doses administered (see Outcome Measure #31). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: Days 1 and 14

  15. Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment. Peak FEV1 was measured in response to all doses administered (see Outcome Measure #32). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

    Time frame: Days 1, 7, and 14

  16. Percentage of the Maximal Response of NVA237 Doses on Trough Forced Vital Capacity on Days 1, 7 and 14

    Percentage of the maximal response of NVA237 Doses on Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was assessed via spirometry. (see Outcome Measure #33). Trough FVC is defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.

    Time frame: Days 1, 7 and 14

  17. Mean Daily Use of Rescue Medication by Treatment at Different Time Points

    Mean daily use of rescue medication by treatment and time points. Baseline was defined as the average of the total number of puffs of rescue medication during the week prior to treatment start, divided by the total number of days with non-missing rescue data during that week, then puffs were counted during weeks 1, 2, 3 and 4 postdose.

    Time frame: Baseline, Weeks 1, 2, 3 and 4

Other outcomes

  1. Trough Forced Expiratory Volume in One Second by Treatment at Day 28

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

    Time frame: Day 28

  2. Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

    Time frame: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28

  3. Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours)

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose). FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

    Time frame: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28

  4. Forced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.

    Time frame: 12 hours on day 28

  5. Peak Forced Expiratory Volume in One Second at Day 28 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Measurements were taken at 25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28.

    Time frame: 25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28

  6. Trough Forced Vital Capacity After 28 Days of Treatment

    Forced Vital Capacity (FVC) after 28 days of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. Trough FVC was defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.

    Time frame: 23 hours 15 mins and 23 hours 45 mins post-dose on Day 28

  7. Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. Trough FEV1 was measured on Days 1, 7 and 14 of treatment. Trough FEV1 was defined as the mean of the FEV1 values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.

    Time frame: 23 hours 15 mins and 23 hours 45 mins post-dose on Days 1, 7 and 14

  8. Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

    Time frame: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14

  9. Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4 hours (postdose) on days 1, 7 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

    Time frame: 5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14

  10. Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

    Time frame: at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14

  11. Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

    Time frame: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14

  12. Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

    Time frame: 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14

  13. Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.

    Time frame: Days 1 and 14

  14. Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment

    Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.

    Time frame: Days 1, 7, and 14

  15. Trough Forced Vital Capacity on Days 1, 7 and 14

    Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. (see Outcome Measure #23). Trough FVC was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

    Time frame: Days 1, 7 and 14

07

Results

Posted Apr 15, 2014

Participant flow

Participants were randomized to 1 of 8 treatment groups during period 1; participants were then switched to a different treatment group during period 2 after a 7 days wash out. Each period lasted up to 29 days.

Participant flow — Overall Study
MilestoneOverall Study
Started388
Nva237 12.5 ug q.d.96
Nva237 25 ug q.d.99
Nva237 12.5 ug b.i.d.99
Nva237 50 ug q.d.96
Nva237 25 ug b.i.d.100
Nva237 100 ug q.d.98
Nva237 50 ug b.i.d.94
Placebo94
Completed341
Not completed47
Withdrew: Adverse event25
Withdrew: Withdrawal by subject9
Withdrew: Protocol violation5
Withdrew: Lost to follow-up4
Withdrew: Administrative2
Withdrew: Abnormal lab value1
Withdrew: Death1

Outcome measures

SecondaryTrough Forced Expiratory Volume in One Second for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. FEV1 was measured between dosing regimens (over the range 20 micrograms to 55 micrograms total daily dose) after 28 days of treatment. Mean trough FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 19), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens. The theoretical responses to each dosing schedule separately and the difference between the once-daily and twice-daily regimens are represented below.

Time frame:
day 28
Reported as:
Mean · Liters
Trough Forced Expiratory Volume in One Second for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237
LitersOverall Study
Total daily dose 20 ug0.037 (0.013 to 0.053)
Total daily dose 25 ug0.037 (0.013 to 0.052)
Total daily dose 30 ug0.036 (0.013 to 0.051)
Total daily dose 35 ug0.035 (0.013 to 0.050)
Total daily dose 40 ug0.034 (0.013 to 0.049)
Total daily dose 45 ug0.033 (0.013 to 0.047)
Total daily dose 50 ug0.032 (0.012 to 0.046)
Total daily dose 55 ug0.031 (0.012 to 0.045)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours at day 28 of treatment was calculated from measurements taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #20). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28
Reported as:
Mean · Percentage of maximal response * hours
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment
Percentage of maximal response * hoursNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment28.9 (18.7 to 41.6)44.8 (31.6 to 58.8)49.0 (34.1 to 64.1)61.9 (48.0 to 74.0)65.7 (50.9 to 78.1)76.4 (64.8 to 85.1)79.3 (67.5 to 87.7)
SecondaryForced Expiratory Volume in One Second AUC 0-24 Hours for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237, After 28 Days of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. The Area Under the Curve (AUC) 0-24 hours FEV1 between dosing regimens over the range 20 micrograms to 55 micrograms total daily dose at -25 min,-15 min (predose); 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. AUC 0-24 hours FEV1 was measured in response to all doses administered (12.5 µg q.d., 25.0 µg q.d., 12.5 µg b.i.d., 50 µg q.d., 25 µg b.i.d., 100 µg q.d., 50.0 µg b.i.d., and Placebo; see Outcome Measure # 20), and was used to compute modeled dose-response curves for once-daily and twice-daily regimens separately. The difference between those curves was computed at pre-specified theoretical doses (20 µg, 25 µg, 30 µg, 35 µg, 40 µg, 45 µg, 50 µg, and 55 µg) chosen at points likely to show the largest differences between the once-daily and twice-daily regimens.

Time frame:
-25 min,-15 min (predose); 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second AUC 0-24 Hours for Once and Twice Daily Regimens of NVA237 for the Same Total Daily Dose of NVA237, After 28 Days of Treatment
LitersOverall Study
Total daily dose 20 ug0.008 (-0.008 to 0.023)
Total daily dose 25 ug0.008 (-0.008 to 0.024)
Total daily dose 30 ug0.008 (-0.008 to 0.024)
Total daily dose 35 ug0.008 (-0.008 to 0.023)
Total daily dose 40 ug0.008 (-0.008 to 0.023)
Total daily dose 45 ug0.008 (-0.008 to 0.022)
Total daily dose 50 ug0.008 (-0.008 to 0.022)
Total daily dose 55 ug0.007 (-0.007 to 0.021)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours) on Day 28

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours were calculated from measurements taken at: 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #21). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28
Reported as:
Mean · Percentage of maximal response* hours
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours) on Day 28
Percentage of maximal response* hoursNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
AUC 0-4h (n=82,90,91,89,92,91,82)50.8 (38.7 to 63.6)66.9 (53.7 to 77.7)58.9 (45.9 to 71.5)79.7 (67.4 to 87.4)73.7 (60.6 to 83.4)88.3 (77.8 to 93.3)84.4 (73.0 to 91.0)
AUC 0-8h (n=82,90,91,90,92,91,82)45.8 (33.2 to 58.8)62.8 (49.9 to 74.1)55.5 (42.0 to 68.4)77.1 (66.6 to 85.1)71.4 (59.1 to 81.2)87.1 (79.9 to 91.9)83.3 (74.3 to 89.7)
AUC 0-12h (n=82,90,91,90,92,91,82)41.1 (28.8 to 54.5)58.3 (44.7 to 70.6)50.5 (37.0 to 64.1)73.6 (61.8 to 82.8)67.1 (54.0 to 78.1)84.8 (76.4 to 90.6)80.3 (70.1 to 87.7)
AUC 12-24h (n=82,90,91,89,92,91,81)25.6 (15.5 to 42.5)40.1 (24.2 to 59.6)56.6 (31.4 to 78.2)56.4 (33.0 to 74.7)71.4 (41.5 to 87.8)71.2 (42.6 to 85.5)82.4 (51.2 to 93.5)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response within different doses/regimens of NVA237 was measured using FEV1 at 12 hours on day 28 of treatment. FEV1 was measured in response to all doses administered (see Outcome Measure #22). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
12 hours on day 28
Reported as:
Mean · Percentage of maximal response
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours at Day 28 of Treatment27.1 (14.7 to 44.6)42.7 (25.7 to 61.7)35.5 (20.4 to 54.0)59.8 (40.9 to 76.3)52.4 (33.9 to 70.2)74.9 (58.0 to 86.6)68.7 (50.7 to 82.5)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Peak FEV1 was measured at day 28 of treatment. Peak FEV1 was measured in response to all doses administered (see Outcome Measure #23). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
day 28
Reported as:
Mean · Percentage of maximal response
Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second at Day 28 of Treatment53.3 (41.2 to 65.5)69.2 (56.7 to 79.2)61.1 (48.2 to 73.4)81.5 (71.1 to 88.4)75.6 (63.4 to 84.7)89.6 (82.4 to 93.9)85.8 (76.5 to 91.7)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment

Percentage of the maximal response of NVA237 within different doses/regimens of NVA237 on Forced Vital Capacity (FVC) was measured at day 28 of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC at day 28 of treatment was measured via spirometry (see Outcome Measure #24). All FVC responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FVC data are reported as a percentage of the theoretical maximal response.

Time frame:
day 28
Reported as:
Mean · Percentage of maximal response
Percentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Percentage of the Maximal Response of NVA237 Doses on Forced Vital Capacity at Day 28 of Treatment23.3 (11.3 to 45.3)37.4 (19.8 to 62.7)53.6 (26.5 to 81.2)54.0 (30.9 to 77.2)69.3 (38.6 to 89.7)69.7 (43.6 to 87.2)81.4 (52.5 to 94.6)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on Trough FEV1 was measured on Days 1, 7 and 14. Through FEV1 was measured in response to all doses administered (see Outcome Measure #25). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

Time frame:
Days 1, 7 and 14
Reported as:
Mean · Percentage of maximal response
Percentage of the Maximal Response of NVA237 Doses on Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n= 88,92,91, 90, 94, 94, 87)28.5 (17.5 to 45.3)43.8 (27.8 to 62.3)63.3 (37.9 to 82.5)60.1 (38.2 to 76.8)76.7 (49.3 to 90.5)74.3 (48.6 to 86.9)86.2 (59.8 to 95.0)
Day 7 (n= 87,92,90, 91, 95, 93, 85)27.1 (16.3 to 44.3)42.0 (26.3 to 61.4)61.6 (36.4 to 82.1)58.5 (37.3 to 76.1)75.5 (48.3 to 90.1)73.0 (48.7 to 86.4)85.4 (59.8 to 94.8)
Day 14 (n= 85,90,91, 88, 94, 93, 81)27.1 (16.4 to 44.3)42.0 (26.4 to 61.4)61.6 (36.6 to 82.1)58.5 (37.4 to 76.1)75.5 (48.5 to 90.2)73.0 (48.8 to 86.5)85.4 (60.1 to 94.8)
SecondaryPercentage of the Maximal Effect of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-24 hours, was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14. FEV1 AUC 0-24 hours was measured on days 1 and 14 of treatment in response to all doses administered (see Outcome Measure #26). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14
Reported as:
Mean · Percentage of maximal response* hours
Percentage of the Maximal Effect of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment
Percentage of maximal response* hoursNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n= 89,94,93,92,96,96,87)38.3 (25.3 to 53.4)55.4 (40.4 to 69.6)59.5 (42.8 to 74.2)71.3 (57.5 to 82.1)74.6 (60.0 to 85.2)83.2 (73.0 to 90.2)85.4 (75.0 to 92.0)
Day 14 (n= 86,92,91,91,95,93,84)28.9 (18.7 to 41.6)44.8 (31.6 to 58.8)49.0 (34.1 to 64.1)61.9 (48.0 to 74.0)65.7 (50.9 to 78.1)76.4 (64.8 to 85.1)79.3 (67.5 to 87.7)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-4 hours was calculated from measurements taken at 5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14, in response to all doses administered (see Outcome Measure #27). All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14
Reported as:
Mean · Percentage of maximal response* hours
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment
Percentage of maximal response* hoursNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n=89,94,93,91,96,96,86)58.4 (44.4 to 71.8)73.2 (59.1 to 83.6)66.1 (51.6 to 78.6)84.1 (72.0 to 91.1)79.1 (65.6 to 88.0)91.1 (81.5 to 95.3)88.0 (77.1 to 93.6)
Day 7 (n=87,93,90,92,95,94,85)50.8 (38.7 to 63.6)66.9 (53.7 to 77.7)58.9 (45.9 to 71.5)79.7 (67.4 to 87.4)73.7 (60.6 to 83.4)88.3 (77.8 to 93.3)84.4 (73.0 to 91.0)
Day 14 (n=86,92,91,91,95,93,84)50.8 (38.7 to 63.6)66.9 (53.7 to 77.7)58.9 (45.9 to 71.5)79.7 (67.4 to 87.4)73.7 (60.6 to 83.4)88.3 (77.8 to 93.3)84.4 (73.0 to 91.0)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #28). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14
Reported as:
Mean · Percentage of maximal response* hours
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14
Percentage of maximal response* hoursNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n=89, 94, 93, 91, 96, 96, 87)54.2 (40.1 to 67.8)70.3 (57.2 to 80.8)63.6 (49.0 to 76.3)82.6 (72.8 to 89.4)77.8 (65.8 to 86.5)90.5 (84.3 to 94.4)87.5 (79.4 to 92.8)
Day 7 (n= 87, 93, 91, 92, 95, 94, 85)45.8 (33.2 to 58.8)62.8 (49.9 to 74.1)55.5 (42.0 to 68.4)77.1 (66.6 to 85.1)71.4 (59.1 to 81.2)87.1 (79.9 to 91.9)83.3 (74.3 to 89.7)
Day 14 (n=86, 92, 91, 91, 95, 93, 84)45.8 (33.2 to 58.8)62.8 (49.9 to 74.1)55.5 (42.0 to 68.4)77.1 (66.6 to 85.1)71.4 (59.1 to 81.2)87.1 (79.9 to 91.9)83.3 (74.3 to 89.7)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14 in response to all doses administered (see Outcome Measure #29). All AUC FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14
Reported as:
Mean · Percentage of maximal response* hours
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment
Percentage of maximal response* hoursNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n=89, 94, 93, 91, 96, 96, 87)49.5 (35.5 to 63.6)66.2 (52.4 to 77.8)58.8 (44.0 to 72.3)79.6 (68.7 to 87.5)74.1 (61.1 to 83.9)88.7 (81.5 to 93.3)85.1 (75.9 to 91.3)
Day 14 (n=86, 92, 91, 91, 95, 93, 84)41.1 (28.8 to 54.5)58.3 (44.7 to 70.6)50.5 (37.0 to 64.1)73.6 (61.8 to 82.8)67.1 (54.0 to 78.1)84.8 (76.4 to 90.6)80.3 (70.1 to 87.7)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14. AUC FEV1 was measured in response to all doses administered (see Outcome Measure #30). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14
Reported as:
Mean · Percentage of maximal response* hours
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment
Percentage of maximal response* hoursNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n=89, 94, 93, 92, 96, 96, 87)23.9 (1.2 to 90.7)37.9 (2.4 to 95.2)54.4 (4.5 to 97.8)54.1 (4.7 to 97.6)69.5 (8.6 to 98.9)69.3 (9.0 to 98.8)81.1 (15.5 to 99.5)
Day 14 (n= 86, 92, 91, 91, 95, 93, 84)25.6 (15.5 to 42.5)40.1 (24.2 to 59.6)56.6 (31.3 to 78.2)56.4 (32.9 to 74.7)71.4 (41.4 to 87.8)71.2 (42.5 to 85.5)82.4 (51.2 to 93.5)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14. FEV1 was measured in response to all doses administered (see Outcome Measure #31). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
Days 1 and 14
Reported as:
Mean · Percentage of maximal response
Percentage of the Maximal Response of NVA237 Doses on Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n=83, 90, 91, 85, 89, 90, 83)35.1 (19.1 to 55.7)52.0 (32.0 to 71.6)44.4 (25.7 to 64.7)68.4 (48.5 to 83.4)61.5 (41.0 to 78.5)81.2 (65.3 to 91.0)76.1 (58.1 to 88.0)
Day 14 (n=84, 91, 88, 90, 90, 92, 78)27.1 (14.7 to 44.6)42.7 (25.7 to 61.7)35.5 (20.4 to 54.0)59.8 (40.9 to 76.3)52.4 (33.9 to 70.2)74.9 (58.0 to 86.6)66.7 (50.7 to 82.5)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment. Peak FEV1 was measured in response to all doses administered (see Outcome Measure #32). All FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All FEV1 data are reported as a percentage of the theoretical maximal response.

Time frame:
Days 1, 7, and 14
Reported as:
Mean · Percentage of maximal response
Percentage of the Maximal Response of NVA237 Doses on Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n=89, 94, 93, 91, 96, 96, 86)61.7 (47.4 to 74.7)76.0 (62.5 to 85.5)68.9 (54.1 to 81.1)86.1 (75.8 to 92.2)81.3 (68.7 to 89.6)92.3 (85.6 to 96.0)89.5 (80.6 to 94.5)
Day 7 (n=87, 93, 90, 92, 95, 94, 85)53.3 (41.2 to 65.5)69.2 (56.7 to 79.2)61.1 (48.2 to 73.4)81.5 (71.1 to 88.4)75.6 (63.4 to 84.7)89.6 (82.4 to 93.9)85.8 (76.5 to 91.7)
Day 14 (n=86, 92, 91, 91, 95, 93, 84)53.3 (41.2 to 65.5)69.2 (56.7 to 79.2)61.1 (48.2 to 73.4)81.5 (71.1 to 88.4)75.6 (63.4 to 84.7)89.6 (82.4 to 93.9)85.8 (76.5 to 91.7)
SecondaryPercentage of the Maximal Response of NVA237 Doses on Trough Forced Vital Capacity on Days 1, 7 and 14

Percentage of the maximal response of NVA237 Doses on Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Trough FVC was assessed via spirometry. (see Outcome Measure #33). Trough FVC is defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.

Time frame:
Days 1, 7 and 14
Reported as:
Mean · Percentage of maximal response
Percentage of the Maximal Response of NVA237 Doses on Trough Forced Vital Capacity on Days 1, 7 and 14
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Day 1 (n=88, 92, 91, 90, 94, 94, 87)22.8 (11.3 to 43.5)36.8 (19.6 to 60.9)52.9 (26.2 to 79.9)53.4 (30.7 to 75.8)68.7 (38.3 to 88.9)69.1 (43.4 to 86.3)81.0 (52.3 to 94.1)
Day 7 (n=87, 92, 90, 91, 95, 93, 85, 87)23.3 (11.2 to 45.2)37.4 (19.6 to 62.5)53.6 (26.3 to 81.2)54.0 (30.7 to 77.1)69.3 (38.3 to 89.7)69.7 (43.3 to 87.1)81.4 (52.0 to 94.6)
Day 14 (n= 85, 90, 91, 88, 94, 93, 81, 84)23.3 (11.3 to 45.3)37.4 (19.7 to 65.5)53.6 (26.4 to 81.2)54.0 (30.8 to 77.1)69.3 (38.5 to 89.7)69.7 (43.5 to 87.2)81.4 (52.2 to 94.6)
SecondaryMean Daily Use of Rescue Medication by Treatment at Different Time Points

Mean daily use of rescue medication by treatment and time points. Baseline was defined as the average of the total number of puffs of rescue medication during the week prior to treatment start, divided by the total number of days with non-missing rescue data during that week, then puffs were counted during weeks 1, 2, 3 and 4 postdose.

Time frame:
Baseline, Weeks 1, 2, 3 and 4
Reported as:
Mean · Number of Puffs
Mean Daily Use of Rescue Medication by Treatment at Different Time Points
Number of PuffsNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Baseline (n=89, 95, 95, 92, 96, 96, 86, 91)4.16 ± 3.1314.16 ± 2.9253.83 ± 3.2184.45 ± 3.0683.47 ± 2.9964.81 ± 3.2764.25 ± 3.6134.62 ± 3.710
Week 1 (n=89, 95, 95, 91, 96, 96, 86, 90)2.41 ± 2.3382.23 ± 2.1582.10 ± 2.3372.36 ± 2.2912.13 ± 2.3492.53 ± 2.6092.54 ± 2.6782.94 ± 3.075
Week 2 (n=86, 94, 94, 91, 95, 93, 84, 89)2.74 ± 2.7842.20 ± 2.0542.22 ± 2.5412.38 ± 2.5412.08 ± 2.5682.59 ± 2.6582.82 ± 3.0033.32 ± 3.455
Week 3 (n= 86, 93, 94, 89, 93, 93, 83, 87)2.75 ± 2.7362.40 ± 2.3162.29 ± 2.3542.37 ± 2.5802.23 ± 2.7432.75 ± 2.8682.69 ± 2.9773.34 ± 3.660
Week 4 (n=86, 92, 94, 88, 93, 93, 82, 85)2.91 ± 2.9682.52 ± 2.4762.42 ± 2.7732.46 ± 2.5042.32 ± 2.9902.65 ± 2.8282.78 ± 2.8993.41 ± 3.761
PrimaryMaximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 28

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. The maximal response of incremental once daily and twice daily doses of NVA237 that each dose achieves in relation to the maximal effect of NVA237 on Trough FEV1 was measured at Day 28. FEV1 was measured in response to all doses administered (see Outcome Measure #19). All trough FEV1 responses to active doses were corrected using the placebo response. A modeled dose response curve was fit to the placebo-corrected data, and extrapolated to estimate the maximal response. All trough FEV1 data are reported as a percentage of the theoretical maximal response. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

Time frame:
Day 28
Reported as:
Mean · Percentage of maximal response
Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 28
Percentage of maximal responseNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.
Maximal Response of Incremental Once Daily and Twice Daily Doses of NVA237 That Each Dose Achieves in Relation to the Maximal Effect of NVA237 on Trough Forced Expiratory Volume in One Second at Day 2827.1 ± 0.45442.0 ± 0.47161.6 ± 0.45658.5 ± 0.38975.5 ± 0.50873.0 ± 0.51285.4 ± 0.463
Other pre-specifiedTrough Forced Expiratory Volume in One Second by Treatment at Day 28

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

Time frame:
Day 28
Reported as:
Mean · Liters
Trough Forced Expiratory Volume in One Second by Treatment at Day 28
LitersNVA237 12.5 ug q.d.NVA237 25 ug q.d.NVA237 12.5 ug b.i.d.NVA237 50 ug q.d.NVA237 25 ug b.i.d.NVA237 100 ug q.d.NVA237 50 ug b.i.d.Placebo
Trough Forced Expiratory Volume in One Second by Treatment at Day 281.319 ± 0.5051.368 ± 0.4361.354 ± 0.4841.340 ± 0.4001.384 ± 0.4721.410 ± 0.5221.493 ± 0.4491.268 ± 0.483
Other pre-specifiedForced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

Time frame:
5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours at Day 28 of Treatment1.307 ± 0.4691.351 ± 0.3921.321 ± 0.4691.317 ± 0.3901.339 ± 0.4621.395 ± 0.4961.457 ± 0.4531.247 ± 0.467
Other pre-specifiedForced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours)

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at: 5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose). FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

Time frame:
5 min,15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on day 28
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second Area Under the Curve at Different Time Points (0-4 Hours, 0-8 Hours, 0-12 Hours, 12-24 Hours)
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
AUC 0-4h (n=82,90,91,89,92,91,82,82)1.415 ± 0.4941.478 ± 0.4391.414 ± 0.4891.431 ± 0.4111.417 ± 0.4871.490 ± 0.5321.553 ± 0.5041.315 ± 0.490
AUC 0-8h (n=82,90,91,90,92,91,82,82)1.386 ± 0.4771.447 ± 0.4231.392 ± 0.4911.397 ± 0.4111.397 ± 0.4761.461 ± 0.5201.527 ± 0.4951.305 ± 0.485
AUC 0-12h (n=82,90,91,90,92,91,82,82)1.364 ± 0.4801.416 ± 0.4161.362 ± 0.4871.377 ± 0.4081.375 ± 0.4691.442 ± 0.5151.505 ± 0.4801.285 ± 0.476
AUC 12-24h (n=82,90,91,89,92,91,81,82)1.251 ± 0.4641.287 ± 0.3821.280 ± 0.4581.264 ± 0.3781.299 ± 0.4591.350 ± 0.4801.421 ± 0.4261.208 ± 0.461
Other pre-specifiedForced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards.

Time frame:
12 hours on day 28
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Forced Expiratory Volume in One Second at 12 Hours on Day 28 of Treatment1.272 ± 0.4711.330 ± 0.4151.279 ± 0.4761.330 ± 0.3841.320 ± 0.4661.391 ± 0.4981.429 ± 0.4491.256 ± 0.472
Other pre-specifiedPeak Forced Expiratory Volume in One Second at Day 28 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Measurements were taken at 25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28.

Time frame:
25 min , 15 min pre-dose, 5 min, 15 min, 1 , 2 ,3 , 4 , 6 , 8 , 10 hours , 11 hour 55 min and 14 hour post-dose on day 28
Reported as:
Mean · Liters
Peak Forced Expiratory Volume in One Second at Day 28 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Peak Forced Expiratory Volume in One Second at Day 28 of Treatment1.500 ± 0.5161.563 ± 0.4531.494 ± 0.5071.514 ± 0.4321.504 ± 0.5161.570 ± 0.5461.630 ± 0.5131.397 ± 0.515
Other pre-specifiedTrough Forced Vital Capacity After 28 Days of Treatment

Forced Vital Capacity (FVC) after 28 days of treatment. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. Trough FVC was defined as the mean of the FVC values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.

Time frame:
23 hours 15 mins and 23 hours 45 mins post-dose on Day 28
Reported as:
Mean · Liters
Trough Forced Vital Capacity After 28 Days of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Trough Forced Vital Capacity After 28 Days of Treatment2.939 ± 0.8783.007 ± 0.9102.954 ± 0.8492.973 ± 0.8253.041 ± 0.7702.974 ± 0.9993.080 ± 0.9132.703 ± 0.857
Other pre-specifiedTrough Forced Expiratory Volume in One Second at Days 1, 7 and 14

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. Trough FEV1 was measured on Days 1, 7 and 14 of treatment. Trough FEV1 was defined as the mean of the FEV1 values measured at 23 hours 15 mins and 23 hours 45 mins post-dose.

Time frame:
23 hours 15 mins and 23 hours 45 mins post-dose on Days 1, 7 and 14
Reported as:
Mean · Liters
Trough Forced Expiratory Volume in One Second at Days 1, 7 and 14
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n= 88,92,91, 90, 94, 94, 87, 86)1.299 ± 0.4901.387 ± 0.4771.375 ± 0.4771.371 ± 0.4061.355 ± 0.5031.367 ± 0.5141.492 ± 0.4831.290 ± 0.471
Day 7 (n= 87,92,90, 91, 95, 93, 85, 87)1.332 ± 0.4991.422 ± 0.4321.349 ± 0.4671.391 ± 0.3921.375 ± 0.4861.372 ± 0.5011.480 ± 0.4741.294 ± 0.491
Day 14 (n= 85,90,91, 88, 94, 93, 81, 84)1.336 ± 0.4421.349 ± 0.4461.335 ± 0.4441.356 ± 0.3911.359 ± 0.4791.375 ± 0.5191.500 ± 0.4551.284 ± 0.471
Other pre-specifiedForced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

Time frame:
5 min, 15 min, 1,2,3,4,6,8,10 hours, 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on days 1 and 14
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second Area Under the Curve 0-24 Hours on Days 1 and 14 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n= 89,94,93,92,96,96,87,90)1.318 ± 0.4701.370 ± 0.4441.354 ± 0.4621.361 ± 0.3931.336 ± 0.4601.376 ± 0.5261.466 ± 0.4711.256 ± 0.469
Day 14 (n= 86,92,91,91,95,93,84,86)1.306 ± 0.4271.353 ± 0.4201.324 ± 0.4301.348 ± 0.3721.335 ± 0.4601.386 ± 0.4931.449 ± 0.4531.253 ± 0.473
Other pre-specifiedForced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Spirometry was performed according to internationally accepted standards. FEV1 Area Under the Curve (AUC) measurements were taken at 5 min, 15 min, 1,2,3,4 hours (postdose) on days 1, 7 and 14 of treatment. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

Time frame:
5 min,15 min, 1,2,3,4 hours (postdose) on Days 1, 7 and 14
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second Area Under the Curve 0-4 Hours on Days 1, 7 and 14 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n=89,94,93,91,96,96,86,89)1.428 ± 0.4921.483 ± 0.4851.421 ± 0.4891.469 ± 0.4281.411 ± 0.4831.453 ± 0.5511.533 ± 0.5011.312 ± 0.494
Day 7 (n=87,93,90,92,95,94,85,89)1.403 ± 0.4681.483 ± 0.4631.397 ± 0.4781.432 ± 0.4071.390 ± 0.4721.453 ± 0.5051.537 ± 0.4941.310 ± 0.491
Day 14 (n=86,92,91,91,95,93,84,86)1.451 ± 0.4561.473 ± 0.4561.390 ± 0.4711.468 ± 0.4091.429 ± 0.5031.460 ± 0.5141.545 ± 0.4851.314 ± 0.500
Other pre-specifiedForced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 Area Under the Curve (AUC) 0-8 was calculated from measurements taken at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7, and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

Time frame:
at 5 min,15 min, 1,2,3,4,6,8 hours (postdose) on days 1, 7 and 14
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second of Area Under the Curve 0-8 Hours Days 1, 7, and 14
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n=89, 94, 93, 91, 96, 96, 87, 90)1.400 ± 0.4861.450 ± 0.4761.401 ± 0.4831.451 ± 0.4261.390 ± 0.4761.446 ± 0.5481.519 ± 0.4931.301 ± 0.488
Day 7 (n= 87, 93, 91, 92, 95, 94, 85, 89)1.386 ± 0.4711.462 ± 0.4551.375 ± 0.4641.409 ± 0.3971.373 ± 0.4701.433 ± 0.5031.516 ± 0.4811.293 ± 0.489
Day 14 (n=86, 92, 91, 91, 95, 93, 84, 86)1.381 ± 0.4531.441 ± 0.4521.375 ± 0.4631.435 ± 0.3981.400 ± 0.4861.442 ± 0.5081.514 ± 0.4791.293 ± 0.498
Other pre-specifiedForced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses was calculated on FEV1 Area Under the Curve (AUC) 0-12 hours from measurements taken at at 5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

Time frame:
5 min,15 min, 1,2,3,4,6,8,10 hours, 11h 55 min (postdose) on days 1 and 14
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second Area Under the Curve 0-12 Hours at Day 1 and 14 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n=89, 94, 93, 91, 96, 96, 87, 90)1.382 ± 0.4881.425 ± 0.4651.379 ± 0.4741.430 ± 0.4211.364 ± 0.4701.431 ± 0.5441.498 ± 0.4841.289 ± 0.482
Day 14 (n=86, 92, 91, 91, 95, 93, 84, 86)1.360 ± 0.4471.416 ± 0.4451.357 ± 0.4521.406 ± 0.3881.378 ± 0.4801.427 ± 0.5031.494 ± 0.4721.281 ± 0.493
Other pre-specifiedForced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 on FEV1 Area under the curve (AUC) 12-24 hours was calculated from measurements taken at 11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14. FEV1 AUC was calculated as the sum of trapezoids divided by the length of time.

Time frame:
11 hours 55 min, 14,20,22 hours; 23 hours 15 min, 23 hours 45 min (postdose) on Days 1 and 14
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second of Area Under the Curve 12-24 Hours Over Days 1, and 14 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n=89, 94, 93, 92, 96, 96, 87, 90)1.257 ± 0.4591.315 ± 0.4321.329 ± 0.4551.295 ± 0.3751.306 ± 0.4541.322 ± 0.5121.437 ± 0.4611.224 ± 0.459
Day 14 (n= 86, 92, 91, 91, 95, 93, 84, 86)1.251 ± 0.4171.289 ± 0.4051.290 ± 0.4151.291 ± 0.3661.291 ± 0.4501.344 ± 0.4881.406 ± 0.4371.225 ± 0.459
Other pre-specifiedForced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Percentage of the maximal response of NVA237 doses on FEV1 at 12 hours was measured on days 1 and 14.

Time frame:
Days 1 and 14
Reported as:
Mean · Liters
Forced Expiratory Volume in One Second at 12 Hours on Days 1 and 14 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n=83, 90, 91, 85, 89, 90, 83, 81)1.319 ± 0.5021.364 ± 0.4521.327 ± 0.4651.345 ± 0.4051.299 ± 0.4571.374 ± 0.5491.439 ± 0.4591.244 ± 0.449
Day 14 (n=84, 91, 88, 90, 90, 92, 78, 83)1.290 ± 0.4311.356 ± 0.4311.303 ± 0.4281.329 ± 0.3681.329 ± 0.4551.389 ± 0.5061.469 ± 0.4361.268 ± 0.477
Other pre-specifiedPeak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Peak FEV1 is the maximum FEV1 recorded in a pre-determined period of time. Percentage of the maximal response of NVA237 doses on Peak FEV1 was measured on days 1, 7 and 14 of treatment.

Time frame:
Days 1, 7, and 14
Reported as:
Mean · Liters
Peak Forced Expiratory Volume in One Second on Days 1, 7 and 14 of Treatment
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n=89, 94, 93, 91, 96, 96, 86, 89)1.503 ± 0.5151.558 ± 0.4971.494 ± 0.5071.541 ± 0.4421.483 ± 0.4951.521 ± 0.5671.597 ± 0.5101.378 ± 0.504
Day 7 (n=87, 93, 90, 92, 95, 94, 85, 89)1.459 ± 0.4771.540 ± 0.4741.455 ± 0.4961.501 ± 0.4261.448 ± 0.4911.513 ± 0.5241.598 ± 0.5101.364 ± 0.504
Day 14 (n=86, 92, 91, 91, 95, 93, 84, 86)1.487 ± 0.4711.547 ± 0.4651.465 ± 0.4841.537 ± 0.4291.506 ± 0.5131.528 ± 0.5291.615 ± 0.4971.380 ± 0.509
Other pre-specifiedTrough Forced Vital Capacity on Days 1, 7 and 14

Trough Forced Vital Capacity (FVC) on Days 1, 7 and 14. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. (see Outcome Measure #23). Trough FVC was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values.

Time frame:
Days 1, 7 and 14
Reported as:
Mean · Liters
Trough Forced Vital Capacity on Days 1, 7 and 14
LitersNVA237 12.5 µg q.d.NVA237 25.0 µg q.d.NVA237 12.5 µg b.i.d.NVA237 50.0 µg q.d.NVA237 25.0 µg b.i.d.NVA237 100.0 µg q.d.NVA237 50.0 µg b.i.d.Placebo
Day 1 (n=88, 92, 91, 90, 94, 94, 87, 86)2.895 ± 0.8303.063 ± 0.9672.997 ± 0.8353.017 ± 0.8202.956 ± 0.8102.944 ± 1.0013.088 ± 0.9612.779 ± 0.838
Day 7 (n=87, 92, 90, 91, 95, 93, 85, 87)2.982 ± 0.8333.135 ± 0.9282.991 ± 0.8733.072 ± 0.8332.993 ± 0.7982.977 ± 0.9873.114 ± 0.9752.759 ± 0.875
Day 14 (n= 85, 90, 91, 88, 94, 93, 81, 84)2.958 ± 0.7723.000 ± 0.9342.965 ± 0.8623.003 ± 0.8122.960 ± 0.7632.941 ± 0.9873.113 ± 0.9412.744 ± 0.841

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237 12.5 ug q.d.—2/89 (2.2%)9/89 (10.1%)
NVA237 25 ug q.d.—2/96 (2.1%)11/96 (11.5%)
NVA237 12.5 ug b.i.d.—1/96 (1%)5/96 (5.2%)
NVA237 50 ug q.d.—3/92 (3.3%)7/92 (7.6%)
NVA237 25 ug b.i.d.—4/96 (4.2%)8/96 (8.3%)
NVA237 100 ug q.d.—3/96 (3.1%)9/96 (9.4%)
NVA237 50 ug b.i.d.—1/87 (1.1%)9/87 (10.3%)
Placebo—3/91 (3.3%)14/91 (15.4%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventNVA237 12.5 ug q.d.NVA237 25 ug q.d.NVA237 12.5 ug b.i.d.NVA237 50 ug q.d.NVA237 25 ug b.i.d.NVA237 100 ug q.d.NVA237 50 ug b.i.d.Placebo
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/890/961/960/922/961/960/870/91
Ventricular extrasystolesCardiac disorders0/890/960/960/920/960/961/870/91
EpididymitisReproductive system and breast disorders1/890/960/960/920/960/960/870/91
Angina pectorisCardiac disorders0/890/960/960/920/960/960/871/91
Herpes zosterInfections and infestations0/890/960/960/920/960/960/871/91
Respiratory tract infectionInfections and infestations0/890/960/960/920/960/960/871/91
Sudden deathGeneral disorders0/890/960/961/920/960/960/870/91
GastroenteritisInfections and infestations0/890/960/961/920/960/960/870/91
Cerebrovascular accidentNervous system disorders0/890/960/961/920/960/960/870/91
Gastrooesophageal reflux diseaseGastrointestinal disorders0/890/960/960/921/960/960/870/91
Most frequent other events
Most frequent other events
EventNVA237 12.5 ug q.d.NVA237 25 ug q.d.NVA237 12.5 ug b.i.d.NVA237 50 ug q.d.NVA237 25 ug b.i.d.NVA237 100 ug q.d.NVA237 50 ug b.i.d.Placebo
NasopharyngitisInfections and infestations4/898/962/964/923/964/965/876/91
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders6/893/961/960/923/962/961/874/91
HeadacheNervous system disorders1/891/962/963/923/964/963/876/91

Baseline characteristics

Baseline/demographic measures are based on safety set

Age, Continuous
Age, Continuous(Years)All Participants
Mean61.2 ± 7.91
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female251
Male135
08

Study locations

29 sites
  • Novartis Investigative Site
    Anniston, Alabama 36201, United States
  • Novartis Investigative Site
    San Diego, California 92101, United States
  • Novartis Investigative Site
    Torrance, California 90501, United States
  • Novartis Investigative Site
    Denver, Colorado 80012, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68104, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19102, United States
  • Novartis Investigative Site
    Antwerpen, Belgium
  • Novartis Investigative Site
    Genk, Belgium
  • Novartis Investigative site
    Jambes, Belgium
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Balassagyarmat, Hungary
  • Novartis Investigative Site
    Balatonfured, Hungary
  • Novartis Investigative Site
    Budapest, Hungary
  • Novartis Investigative Site
    Debrecen, Hungary
  • Novartis Investigative Site
    Szolnok, Hungary
  • Novartis Investigative Site
    Torokbalint, Hungary
  • Novartis Investigative Site
    Almelo, Netherlands
  • Novartis Investigative Site
    Eindhoven, Netherlands
  • Novartis Investigative Site
    Harderwijk, Netherlands
  • Novartis Investigative Site
    Heerlen, Netherlands
  • Novartis Investigative Site
    Helmond, Netherlands
  • Novartis Investigative Site
    Veldhoven, Netherlands
  • Novartis Investigative Site
    Zutphen, Netherlands
  • Novartis Investigative Site
    Izabelin, Poland
  • Novartis Investigative Site
    Lodz, Poland
  • Novartis Investigative Site
    Warszawa, Poland
  • Novartis Investigative Site
    Alicante, Spain
  • Novartis Investigative Site
    La Coruña, Spain
  • Novartis Investigative Site
    Ponferrada, Spain
09

References and documents

Publications

  • Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M, Banerji D. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012 Dec 8;12:74. doi: 10.1186/1471-2466-12-74. PubMed 23217058 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 3 years 4 months after primary completion. A results delay was requested in Oct 2011.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2010
First posted
May 10, 2010
Start
Apr 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results delay requested
Oct 24, 2011
Results first posted
Apr 15, 2014
Last update
Mar 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01119950
Responsible party
Sponsor
First posted
May 10, 2010
Start date
Apr 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Apr 15, 2014
Last update
Mar 23, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion